Working hours:
Mon-Fri: 9 a.m.- 6 p.m.
Call me back

Pomahope 4mg (Pomalidomide )

Rating:
Availability:
In stock
Quantity:
+
0,00 $
Shipping methods

New Post

Other transport services

Courier in Kiev

Pickup

Payment methods

Cash

Non-cash transfer

Privat 24

WebMoney

POMAHOPE 4MG

POMAHOPE 4MG REFER AS

Pomahope 4mg is an antineoplastic drug, which is used by the patients who are having a valid prescription and under the supervision of medical oncologist.

Pomahope 4mgaffects the immune system. It encourages immune responses to help reduce tumor growth.

POMAHOPE 4MG THERAPEUTIC INDICATIONS

The primary indication of Pomahope 4mg is used in the treatment of Multiple Myeloma condition.

In this condition, Pomahope 4mg is used by interaction with dexamethasone.

Pomahope 4mg capsules are indicated in Patients already got therapy with two medications such as proteasome inhibitor & Lenalidomide. followed within 60 days in patients who are concluded the last treatment.

DOSAGE OF POMAHOPE 4MG

Pomahope tablets are available in the strength of 1mg, 2mg and 4mg

In adults

Pomalidomide is a thalidomide analogue; it is used in combination with dexamethasone

The recommended dose of Pomahope tablets in multiple myeloma condition, 4mg should be taken orally as a single dose on days 1-21 of repeated 28 days cycles until disease advancement

Pomahope given in combination with low dose of dexamethasone

Dexamethasone should be given orally only in days of 1, 8, 15 and 22 of each 28 days

>75 years: 20mg/day

≤75 years: 40mg/day

Dose modification:

Pomalidomide therapy should be discontinue, if toxicities occur after dose reduction to 1mg (in case of neutropenia and thrombocytopenia)

In pediatric

<18 years: the safety and efficacy of the Pomahope tablets has been established

Administration

Pomahope tablets should be taken with water; it should not chew, break or open

Pomahope should be taken with or without food

With strong CYP1A2

Pomahope combined with CYP1A2 substrates causes increasing the plasma concentration of Pomalidomide and leads to elevate the risk of Pomalidomide.

OVER DOSAGE

No specific antidote is used for over dosage of Pomalidomide. Patient should be provided with general supportive measures. Monitor the signs & symptoms

SIDE EFFECTS OF POMAHOPE 4MG

  • Difficult, frequent, or painful urination
  • pale skin
  • rash, itching, hives
  • nosebleed
  • GIT problems: constipations, diarrhea, nausea, vomiting
  • Life changes: decrease appetite, weight changes, uncontrollable shaking of a part of the body, night sweats
  • Anxiety
  • Insomnia
  • Arthralgia, myalgia
  • swelling of the eyes, face, tongue, throat, hands, arms, feet, ankles, or lower legs
  • difficulty breathing or swallowing
  • hoarseness
  • fever, sore throat, chills, cough, or other signs of infection
  • yellow eyes or skin
  • dark urine
  • pain or discomfort in the right upper stomach area

POMAHOPE 4MG DRUG INTERACTION;

Pomahope 4mg combination with CYP1A2 drugs causes increased concentration of Pomalidomide.

Overcome this problem by decreasing the dose of Pomahope 4mg during this combination therapy.

POMAHOPE 4MG WORKS AS

Thalidomide associate which evoke immunomodulatory and antineoplastic activity; it prohibits replication and induced apoptosis of hematopoietic tumor cells

Additionally, it increases T-cell and natural killer cell-mediated immunity and restrain production of TNF-alpha and interleukin-6; down-modulates cell surface adhesion molecules contain in leukocyte migration.

Anticancer activity may be due to inhibition of angiogenesis

Pomahope 4mg ADME properties

Absorption: The peak plasma concentration time of Pomalidomide is arrives between 2 to 3 hours.

Distribution: Pomalidomide is bounded to human plasma protein by range of 12% & 44%.

Metabolism: The metabolism of Pomalidomide is appears via hepatically mediated through CYP1A2, CYP3A4.

Elimination: The Pomalidomide clearance value is 7 to 10L/hr.

Doses are excreted via urine 73% & feces 15% respectively.

Doses are excreted as in unchanged form through urine 2% & feces 8%.

The half-life period of Pomalidomide is 9.5 hours

POMAHOPE 4MG CONTRAINDICATION

Pomahope 4mg is contraindicated to;

Pregnancy

Lactation

Hypersensitivity reactions produced due to patients are contraindicated to the component of Pomahope 4mg.

SAFETY PRECAUTIONS

  • During Pomahope 4mg treatment, there is a possibility of elevation of hepatic enzymes occurs. This may have reported as increased liver toxicity.
  • Pomahope 4mg should not be used during pregnancy will causes Teratogenicity, organogenesis and causes fetal damage. Do not becoming pregnant during Pomahope 4mg treatment by using effective contraceptives.
  • Deep vein thrombosis is harm while occurs during the Pomahope 4mg treatment. Thromboprophylaxis is started for this condition. Increase of mortality in case of pembrolizumab taken with thalidomide & dexamethasone;
  • Neutropenia, thrombocytopenia is main common side effects occur during the Pomahope 4mg treatment. These may counteract by checking the blood counts frequently and postponement of dosage or adjustment of dose is necessary.
  • Instruct the patients to keep away from circumstances where unsteadiness or disturbed state might be an issue and not to take different meds that may leads to dazedness or disturbed state without adequate therapeutic exhortation.

POMAHOPE 4MG USES IN

Pregnancy

Pregnancy category of Pomahope 4mg is X. Pomahope 4mg usage during pregnancy period, leads to fetal harm and causes death.

Lactation

Breast feeding should not be recommended.

POMAHOPE 4MG STORAGE CONDITION

The Pomahope 4mg capsules container should be stored at 20oC to 25oC

Protect the container from moisture, heat, & light.

MISSED DOSE

If missed dose occurs, consult with physician & follow the regular dosing schedule. Or skip the missed dose and follow the routine timing. Otherwise Missed dose leads to over dosage condition.

  • Trade name Pomahope 4mg
  • Substance Pomalidomide
  • Manufacturer Abbott India Ltd
  • Packaging 21 capsules
  • Country of origin India
No comments yet
Write a comment
Name*
Email
Enter your comment*
10 + ? = 20
Enter Captcha*
Recommend